Cite
HARVARD Citation
Yap, T. et al. (n.d.). Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. European journal of cancer. pp. S2-. [Online].